Takeda And Par Drug Makers Withheld Generic Drug At The Public Interests’ Expense
A latest class action lawsuit is accusing the drug companies Takeda Pharmaceutical and Par Pharmaceutical of deliberately putting patients at a disadvantage as they allegedly delayed the release of a generic version of their anti-constipation medicine Amitiza.
Takeda & Par Pharmaceuticals Chose To Not Release Generic Drug, Harming Patients
Per reports, both Takeda and Par Pharmaceutical companies are in trouble after they reportedly did not act swiftly to make their drug available to the public. Documents showed that Takeda Pharmaceutical reportedly paid Par Pharmaceutical to allegedly delay the release of the generic make of Amitiza for more than six years running.
Filed by FWK Holdings and Meijer, Inc., the two companies have contended that the two, Takeda and Par, have conducted gross acts that are tantamount to violations of different antitrust laws.
Takeda Pharmaceuticals first got their anti-constipation drug Amitiza approved by the authorities over the FDA (Food and Drug Administration) back in 2006.
Takeda’s Amitiza is regarded by medical experts and practitioners as an effective medicine to help patients suffering from different unintended side effects brought upon by chronic constipation due to the consumption of opioids.
Following four years, Par went to the FDA to petition the regulatory board to grant them the permission to allow them to manufacture a generic version of Takeda’s Amitiza drug.
Takeda vehemently disagreed with the request and launched a legal battle to hold off other companies and their ambitions of producing a much cheaper version of Amitiza to be released to the general public.
Deadly Partnership Hurt General Public’s Needs
The two companies reportedly entered into a settlement agreement in the same year of the litigation. It resulted in the two agreeing that Par would not release a generic Amitiza to the consumer market until 2021. According to estimates released, the settlement agreement was tallied to at least $29 million to up to $280 million.
However, the plaintiffs argued that patients and everyday consumers were robbed of the opportunity of availing a much cheaper drug during the six years Takeda and Par agreed to withhold the generic version of the drug to the market.
About The Defendants
Takeda Pharmaceutical Company Limited is Asia’s largest drugmaker, and it belongs to the top 20 list of largest pharmaceutical manufacturers all over the globe by recorded revenue.
Founded more than two centuries ago, the company is headquartered in Tokyo, Japan, with multiple offices and subsidiaries worldwide. Christophe Weber currently heads Takeda as their CEO since his ascension in 2015.
Meanwhile, Par Pharmaceutical is a generics drug company based in New York. The company was founded in 2003. Now, the company is under its parent company Endo International.
Editor’s Note on Takeda Amitiza Class Action Lawsuit 2021:
This feature details the latest class action filed against two drug manufacturers, namely Takeda Pharmaceutical and Par Pharmaceutical, after they both worked together to deprive the public of a cheaper alternative to Amitiza drug in the name of controlling the market.
Case Name(s) & No.: FWK Holdings LLC, et al. v. Takeda Pharmaceutical Company Ltd., et al.; Case No.: 1:21-cv-11057
Jurisdiction: United States District Court for the District of Massachusetts
Products/Services Involved: Takeda Pharmaceutical’s Amitiza
Allegation(s): Amitiza’s generic version has not been released to the public due to Takeda and Par’s deal to hold off its release on purpose.
What are your thoughts on this piece? Please send us a message by clicking the ‘Contact Us’ button below! We’d love to hear back from you.
Suggested Article: Johnson & Johnson Opioid Settlement For $230 Million – 2021.